On 2016 Feb 15, David Keller commented:

Urologists have the most expertise at detecting curable prostate cancer

The USPSTF recommendation against screening for prostate cancer using the PSA blood test was based on two large randomized studies which were hindered by poor compliance and design flaws [1]. Further, the widespread use of PSA testing has been accompanied by a 40% drop in deaths from prostate cancer, which is not adequately explained by any other factor. Now, this study informs us that urologists continue to employ the PSA test more often than primary care physicians. Since urologists generally have the most experience in the detection and early cure of prostate cancer, it is reasonable for primary-care physicians to emulate their practices, at least until credible results are obtained from properly designed and executed randomized trials.

Reference

1: Allan GM, Chetner MP, Donnelly BJ, Hagen NA, Ross D, Ruether JD, Venner P. Furthering the prostate cancer screening debate (prostate cancer specific mortality and associated risks). Can Urol Assoc J. 2011 Dec;5(6):416-21. doi: 10.5489/cuaj.11063. PubMed PMID: 22154638; PubMed Central PMCID: PMC3235209.

On 2016 Feb 15, David Keller commented:

Urologists have the most expertise at detecting curable prostate cancer

The USPSTF recommendation against screening for prostate cancer using the PSA blood test was based on two large randomized studies which were hindered by poor compliance and design flaws [1]. Further, the widespread use of PSA testing has been accompanied by a 40% drop in deaths from prostate cancer, which is not adequately explained by any other factor. Now, this study informs us that urologists continue to employ the PSA test more often than primary care physicians. Since urologists generally have the most experience in the detection and early cure of prostate cancer, it is reasonable for primary-care physicians to emulate their practices, at least until credible results are obtained from properly designed and executed randomized trials.

Reference

1: Allan GM, Chetner MP, Donnelly BJ, Hagen NA, Ross D, Ruether JD, Venner P. Furthering the prostate cancer screening debate (prostate cancer specific mortality and associated risks). Can Urol Assoc J. 2011 Dec;5(6):416-21. doi: 10.5489/cuaj.11063. PubMed PMID: 22154638; PubMed Central PMCID: PMC3235209.